Health-related quality of life among patients with stage 3 melanoma was not significantly affected after receiving ...

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...

Merck & Co.’s drug Keytruda failed to help people with cancer in two clinical trials, both using the immunotherapy as an add-on to other types of treatment for early-stage lung and skin cancer ...

The combo treatment reduced the risk of death by 21% at the trial's final analysis. Adverse reactions were generally similar to those in other patients receiving Keytruda and chemotherapy ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

This year, Merck's combination immunotherapy of vibostolimab and Keytruda faced two separate trial discontinuations when evaluated as treatments for lung and skin cancer. In recent months ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Today we highlight research findings reported at ESMO 2024, the annual meeting of the European Society of Medical Oncology.

Recommended Reading Biomarker data help Merck case for wide use of Keytruda combo Merck ... as an add-on to other types of treatment for early-stage lung and skin cancer, the comapny said ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...